Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer.
immune checkpoint inhibitors
immunotherapy
new drugs
ovarian cancer
platinum-resistance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
received:
08
03
2021
revised:
27
03
2021
accepted:
30
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and other targeted agents. The role of immunotherapy in the treatment of platinum-resistant OC remains undefined. The aim of this review is to describe the immunobiology of OC and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration, as well as provide an overview of future drug development strategies.
Identifiants
pubmed: 33916221
pii: cancers13071663
doi: 10.3390/cancers13071663
pmc: PMC8037571
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Mol Pharmacol. 2005 May;67(5):1485-92
pubmed: 15703384
Eur J Cancer. 2017 Jan;70:111-121
pubmed: 27914241
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Oncogene. 2012 Oct 18;31(42):4567-76
pubmed: 22249249
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10
pubmed: 18287062
Ann Oncol. 2017 Apr 1;28(4):727-732
pubmed: 27993805
J Clin Oncol. 2012 Jul 20;30(21):2654-63
pubmed: 22711857
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
Int J Gynecol Cancer. 2019 May;29(4):705-710
pubmed: 30772826
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
J Hematol Oncol. 2019 Sep 14;12(1):98
pubmed: 31521196
J Oncol. 2019 Mar 20;2019:5483791
pubmed: 31015835
Eur J Cancer. 2016 Mar;55:65-73
pubmed: 26773421
Front Oncol. 2019 Oct 09;9:1004
pubmed: 31649875
BMC Cancer. 2020 Aug 10;20(1):748
pubmed: 32778095
Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4411-6
pubmed: 25831546
JAMA Oncol. 2019 Oct 10;:
pubmed: 31600397
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Oncotarget. 2016 Jan 12;7(2):1486-99
pubmed: 26625204
Int J Gynecol Cancer. 2016 Feb;26(2):240-7
pubmed: 26745696
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
J Interferon Cytokine Res. 2016 Jan;36(1):62-73
pubmed: 26430781
J Clin Oncol. 1997 Jun;15(6):2183-93
pubmed: 9196130
Clinics (Sao Paulo). 2018 Sep 06;73(suppl 1):e478s
pubmed: 30208165
Clin Cancer Res. 2019 Jun 1;25(11):3210-3219
pubmed: 30670489
Anticancer Drugs. 2019 Jul;30(6):628-635
pubmed: 31008727
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Sci Rep. 2019 Oct 31;9(1):15767
pubmed: 31673068
Cancers (Basel). 2018 Jul 24;10(8):
pubmed: 30042343
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Cancer Res. 2000 Nov 1;60(21):6039-44
pubmed: 11085525
Lancet Oncol. 2019 Aug;20(8):e417-e433
pubmed: 31364594
J Ovarian Res. 2020 Mar 11;13(1):27
pubmed: 32160916
Ann Oncol. 2017 Nov 1;28(suppl_8):viii8-viii12
pubmed: 29232468
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Emerg Top Life Sci. 2017 Dec 12;1(5):429-445
pubmed: 33525803
Clin Cancer Res. 2018 May 15;24(10):2285-2293
pubmed: 29500276
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
Gynecol Oncol. 2014 Feb;132(2):506-12
pubmed: 24333356
Sci Rep. 2017 Mar 07;7:42929
pubmed: 28266500
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
J Cell Mol Med. 2018 May 31;:
pubmed: 29855141
Int J Womens Health. 2013;5:45-51
pubmed: 23378788
Fam Cancer. 2001;1(2):107-9
pubmed: 14574006
J Clin Oncol. 2017 Oct 10;35(29):3347-3353
pubmed: 28825853
Oncoimmunology. 2015 Jan 23;4(3):e994446
pubmed: 25949921
Oncologist. 2020 Jan;25(1):e160-e169
pubmed: 31395751
Oncogene. 2018 Aug;37(33):4611-4625
pubmed: 29760405
Gynecol Oncol. 2017 Oct;147(1):61-65
pubmed: 28779965
Gynecol Oncol. 2016 Aug;142(2):225-30
pubmed: 27208536
J Immunother Cancer. 2019 Jul 15;7(1):183
pubmed: 31307554
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7
pubmed: 22006311
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Oncotarget. 2015 Sep 29;6(29):27359-77
pubmed: 26318293
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
J Clin Oncol. 2020 Jun 1;38(16):1814-1823
pubmed: 32275468
Eur J Cancer. 2019 Aug;117:14-31
pubmed: 31229946
Cancer Sci. 2020 Apr;111(4):1324-1332
pubmed: 32012411
Gynecol Oncol. 2016 Oct;143(1):120-127
pubmed: 27470997
Oncogene. 1999 Apr 8;18(14):2335-41
pubmed: 10327053
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Gynecol Oncol. 2020 Aug;158(2):484-488
pubmed: 32518015
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
JAMA Oncol. 2018 Feb 1;4(2):196-202
pubmed: 29242937
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Nat Med. 2018 May;24(5):556-562
pubmed: 29736026
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Mod Pathol. 2017 Nov;30(11):1622-1632
pubmed: 28752845
BMC Cancer. 2017 Jun 30;17(1):456
pubmed: 28666422
J Cell Physiol. 2003 Jun;195(3):346-55
pubmed: 12704644
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Gynecol Oncol. 2014 Jun;133(3):624-31
pubmed: 24607285
J Clin Oncol. 2007 Jul 1;25(19):2811-8
pubmed: 17602086
Lancet Oncol. 2020 Dec;21(12):1661-1672
pubmed: 33271095
Cancers (Basel). 2020 Aug 25;12(9):
pubmed: 32854242
Oncol Rep. 2005 Jun;13(6):1153-8
pubmed: 15870936
Nat Rev Cancer. 2009 Jun;9(6):445-52
pubmed: 19461669
Annu Rev Med. 2015;66:97-110
pubmed: 25341012
Lancet Oncol. 2020 Sep;21(9):1155-1164
pubmed: 32771088
Int J Mol Sci. 2019 Aug 24;20(17):
pubmed: 31450627
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Oncotarget. 2018 Apr 3;9(25):17501-17511
pubmed: 29707124
J Clin Oncol. 2015 Nov 10;33(32):3836-8
pubmed: 26282651
Br J Cancer. 2009 Nov 3;101(9):1513-21
pubmed: 19861998
JAMA Oncol. 2019 Jun 13;:
pubmed: 31194228
Clin Cancer Res. 2014 Mar 1;20(5):1125-34
pubmed: 24323902
Science. 2018 Mar 23;359(6382):1344-1345
pubmed: 29567702
Cancer Lett. 2018 Jul 28;427:9-17
pubmed: 29660381
Genes Environ. 2020 Feb 28;42:9
pubmed: 32161626
Gynecol Oncol. 2015 Jul;138(1):55-61
pubmed: 25895616
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Pharmacol Rev. 2012 Jul;64(3):706-21
pubmed: 22659329
J Pathol. 2018 Apr;244(5):550-564
pubmed: 29344971
Biomark Cancer. 2019 Jul 05;11:1179299X19860815
pubmed: 31308780
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Gynecol Oncol. 2019 Feb;152(2):243-250
pubmed: 30522700
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
DNA Repair (Amst). 2005 May 2;4(5):583-93
pubmed: 15811630
Gynecol Oncol. 2004 Feb;92(2):622-7
pubmed: 14766256
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348
Front Immunol. 2019 Apr 26;10:867
pubmed: 31105696
BMC Cancer. 2014 Dec 13;14:947
pubmed: 25495785